CN105434467A - Chilblain therapeutic agent and production method thereof - Google Patents
Chilblain therapeutic agent and production method thereof Download PDFInfo
- Publication number
- CN105434467A CN105434467A CN201510899238.7A CN201510899238A CN105434467A CN 105434467 A CN105434467 A CN 105434467A CN 201510899238 A CN201510899238 A CN 201510899238A CN 105434467 A CN105434467 A CN 105434467A
- Authority
- CN
- China
- Prior art keywords
- powder
- chilblain
- therapeutic agent
- perniosis
- stone needle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000010445 Chilblains Diseases 0.000 title claims abstract description 41
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 15
- 239000003814 drug Substances 0.000 title claims abstract description 10
- 229940124597 therapeutic agent Drugs 0.000 title claims abstract description 10
- 239000000843 powder Substances 0.000 claims abstract description 32
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims abstract description 25
- 239000004575 stone Substances 0.000 claims abstract description 24
- 229910052709 silver Inorganic materials 0.000 claims abstract description 9
- 239000004332 silver Substances 0.000 claims abstract description 9
- 239000000463 material Substances 0.000 claims abstract description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 23
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 13
- 239000002674 ointment Substances 0.000 claims description 8
- 229940099259 vaseline Drugs 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 3
- 230000017531 blood circulation Effects 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 230000001954 sterilising effect Effects 0.000 abstract description 3
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 2
- 208000025865 Ulcer Diseases 0.000 description 6
- 231100000397 ulcer Toxicity 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- CPBQJMYROZQQJC-UHFFFAOYSA-N helium neon Chemical compound [He].[Ne] CPBQJMYROZQQJC-UHFFFAOYSA-N 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000009724 venous congestion Effects 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N2/00—Magnetotherapy
- A61N2/002—Magnetotherapy in combination with another treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N2/00—Magnetotherapy
- A61N2/06—Magnetotherapy using magnetic fields produced by permanent magnets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0625—Warming the body, e.g. hyperthermia treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
- A61N2005/066—Radiation therapy using light characterised by the wavelength of light used infrared far infrared
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0004—Applications of ultrasound therapy
- A61N2007/0017—Wound healing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0004—Applications of ultrasound therapy
- A61N2007/0034—Skin treatment
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Inorganic Chemistry (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Radiation-Therapy Devices (AREA)
Abstract
The invention discloses a chilblain therapeutic agent and a production method thereof. The chilblain therapeutic agent is prepared from, by weight percentage, 0.05-0.1% of silver powder, 30-60% of stone needle powder and 40-70% of magnet powder. The stone needle in the chilblain therapeutic agent can emit far infrared and ultrasonic pulse, the magnet can accelerate blood flow, and silver has a sterilization effect. The chilblain therapeutic agent is smeared or worn on the part attacked by a disease and saves force and time, no power is used, and the chilblain therapeutic agent is easy to implement. The materials of the chilblain therapeutic agent are environmentally friendly and safe and have no side effect, and the chilblain therapeutic agent is a good product for users receiving chilblain treatment.
Description
Technical field
The present invention relates to medical art, particularly relate to a kind for the treatment of of perniosis agent and production method thereof.
Background technology
Cold is the main cause of chilblain morbidity, and when the limbs of chilblain patient are when running into cold (less than 0-10 DEG C), when humidity and the changes in temperature sudden turn of events, local small artery shrinks, and arteries is benumbed and expands, venous congestion, and local blood circulation is bad and fall ill.Patient's autologous skin humidity, tip blood capillary deformity, autonomic nerve dysfunction, malnutrition, the factors such as dyshormonia may participate in morbidity.Do not get enough athletic exercise, acrohyperhidrosis is moist, and the factors such as footgear tension and outdoor low operating temperatures also can cause chilblain and occur.With peripheral blood circulation, bad person is common.Common infringement is limitation congestive mulberry redness protuberance property erythema, and indefinite border, edge is cerise, and surface is nervous glossy, and matter is soft, and local pressing can be faded, and goes to press rear recovery, severe patient generation blister, breaks and forms rotten to the corn or ulcer.Gargalesthesia is obvious, and pain after festering, also has the above-mentioned symptom occurring in women thigh, but also sees in blue infiltrating speckle, occasionally has Secondary cases ulcer and merges horny follicular plug.For above-mentioned symptom, medical personnel gives these patients various different Therapeutic Method.As oral nicotiamide, the vasodilation such as nifedipine and Radix Salviae Miltiorrhizae and quiet of low molecular dextran etc.Topical therapeutic helium-neon laser irradiation, or laser point irradiation etc.To ulcer spot, with hirudiod, vitamin E ointment etc., and with herbal medicine immersion etc.These remedy measures have certain therapeutical effect to above-mentioned chilblain, but some methods such as oral administration can not going directly suffers from position, and do not reach curative effect, have etc. general take a turn for the better and just show curative effect, patient often waits for for a long time.
Summary of the invention
An object of the present invention overcomes the deficiencies in the prior art, and provide a kind of to promote blood circulation, it is main for infecting for ulcer, chilblain position can be made to recover normal presentation, functional rehabilitation treatment of perniosis agent faster.
In order to solve the problems of the technologies described above, the technical solution adopted in the present invention is:
A kind for the treatment of of perniosis agent, takes off the manufacture of materials stating weight proportion and forms: argentum powder 0.05-0.1%, stone needle powder 30-60%, magnetic iron powder 40-70%.
Above-mentioned treatment of perniosis agent preferably, is that carrier makes ointment with vaseline.
Another object of the present invention is to provide the production method of above-mentioned treatment of perniosis agent.
A production method for treatment of perniosis agent, step is as follows:
Step one: by silver micronization processes at 80-100 DEG C of temperature, refinement causes 1-3 nanometer and obtains argentum powder;
Step 2: by stone needle micronization processes at 80-100 DEG C of temperature, refinement causes 1-100 nanometer and obtains stone needle powder;
Step 3: by Magnet micronization processes at 80-100 DEG C of temperature, crosses 120 mesh sieves, obtains magnetic iron powder;
Step 4: after the magnetic iron powder mix homogeneously that the stone needle powder that argentum powder step one obtained, step 2 obtain, step 3 obtain, add the sterile vaseline of above-mentioned raw materials weight 95%-100%, the obtained unguentum perniosis agent of mixing.
Raw materials of the present invention and function as follows:
Argentum powder: silver has special dissipation effect to microorganism (antibacterial, virus etc.).According to surveying and determination, the silver of part per billion milligram, can kill live bodies all in 1 premium on currency.
Stone needle powder: containing tens kinds, strontium, titanium, chromium, zinc etc. to the useful trace element of human body and mineral element and terres rares, significantly can accelerate the blood flow rate of nail fold microcirculation; Its value added reach more than 20% and also effect be lasting; Stone needle can send the far-infrared electromagnetic wave peak value 9.8 microns of 20,000-200 hertz, and far infrared all has improvement and preventive effect for the various diseases that blood circulation and circulatory disturbance cause; And the ultrasonic pulse of 20,000-200 hertz can be produced, penetrance is 92.8%, and the vibration number of human body being swiped once is 4106 times, and without harmful element, radioelement, and the unusual energy field of stone needle can be followed footpath and go, dredging the meridian.
Magnetic iron powder: the ferrous components having trace in the blood of people, and Magnet is under the effect of ferromagneticization, repulsion, captivation, accelerates blood flow, reach reduce blood pressure, the object of blood circulation promoting and blood stasis dispelling.
With prior art ratio, beneficial effect of the present invention is:
Stone needle in treatment of perniosis agent of the present invention, can emitter stage far infrared and ultrasonic pulse, and Magnetitum can accelerate blood flow, and silver has sterilization functions simultaneously, and this therapeutic agent is smeared or is worn on disease sites, laborsavingly saves time, and does not use power, easily carries out; And the material environment friendly for the treatment of of perniosis agent of the present invention safely, have no side effect, be a kind of product preferably to treatment of perniosis person.
Detailed description of the invention
Describe technical scheme of the present invention in detail below in conjunction with embodiment and experimental example, but protection domain is not by this restriction.
embodiment 1a kind for the treatment of of perniosis agent, the manufacture of materials of getting following weight forms: argentum powder 0.2g, stone needle powder 30g, magnetic iron powder 70g.
The production method of above-mentioned treatment of perniosis agent, step is as follows:
Step one: by silver micronization processes at 80 DEG C of temperature, refinement causes 3 nanometers and obtains argentum powder;
Step 2: by stone needle micronization processes at 80 DEG C of temperature, refinement causes 100 nanometers and obtains stone needle powder;
Step 3: by Magnet micronization processes at 80 DEG C of temperature, crosses 120 mesh sieves, obtains magnetic iron powder;
Step 4: after the magnetic iron powder mix homogeneously that the stone needle powder that argentum powder step one obtained, step 2 obtain, step 3 obtain, add 98g sterile vaseline, the kibe ointment 200g of the obtained argentiferous 0.1% of mixing.
Treatment of perniosis agent silver composition in this embodiment is high, improves sterilizing function, as ulcer occurs at chilblain position, be easily infected by bacterial or be infected by bacterial, should treat with the kibe ointment of embodiment 1 formula during to treat chilblain.
embodiment 2a kind for the treatment of of perniosis agent, the manufacture of materials of getting following weight forms: argentum powder 0.1g, stone needle powder 40g, magnetic iron powder 60g.
The production method of above-mentioned treatment of perniosis agent, step is as follows:
Step one: by silver micronization processes at 100 DEG C of temperature, refinement causes 3 nanometers and obtains argentum powder;
Step 2: by stone needle micronization processes at 100 DEG C of temperature, refinement causes 100 nanometers and obtains stone needle powder;
Step 3: by Magnet micronization processes at 100 DEG C of temperature, crosses 120 mesh sieves, obtains magnetic iron powder;
Step 4: after the magnetic iron powder mix homogeneously that the stone needle powder that argentum powder step one obtained, step 2 obtain, step 3 obtain, add 99.9g sterile vaseline, the unguentum perniosis agent of the obtained argentiferous 0.05% of mixing.
In this embodiment there is not ulcer in chilblain part, but obviously become red and swollen or occur other symptoms occurred because blood circulation is smooth, and the treatment of perniosis agent in employing embodiment 2 is to accelerate blood flow.
Claims (5)
1. a treatment of perniosis agent, is characterized in that: take off the manufacture of materials stating weight proportion and form: argentum powder 0.05-0.1%, stone needle powder 30-60%, magnetic iron powder 40-70%.
2. a treatment of perniosis agent, is characterized in that: take off the manufacture of materials stating weight proportion and form: argentum powder 0.2g, stone needle powder 30g, magnetic iron powder 70g.
3. a treatment of perniosis agent, is characterized in that: take off the manufacture of materials stating weight proportion and form: argentum powder 0.1g, stone needle powder 40g, magnetic iron powder 60g.
4. a kind for the treatment of of perniosis agent according to any one of claim 1-3, is characterized in that: therapeutic agent is that carrier makes ointment with vaseline.
5. the production method of a kind for the treatment of of perniosis agent according to claim 1, is characterized in that: step is as follows:
Step one: by silver micronization processes at 80-100 DEG C of temperature, refinement causes 1-3 nanometer and obtains argentum powder;
Step 2: by stone needle micronization processes at 80-100 DEG C of temperature, refinement causes 1-100 nanometer and obtains stone needle powder;
Step 3: by Magnet micronization processes at 80-100 DEG C of temperature, crosses 120 mesh sieves, obtains magnetic iron powder;
Step 4: after the magnetic iron powder mix homogeneously that the stone needle powder that argentum powder step one obtained, step 2 obtain, step 3 obtain, add the sterile vaseline of above-mentioned raw materials weight 95%-100%, the obtained unguentum perniosis agent of mixing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510899238.7A CN105434467A (en) | 2015-12-09 | 2015-12-09 | Chilblain therapeutic agent and production method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510899238.7A CN105434467A (en) | 2015-12-09 | 2015-12-09 | Chilblain therapeutic agent and production method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105434467A true CN105434467A (en) | 2016-03-30 |
Family
ID=55545401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510899238.7A Pending CN105434467A (en) | 2015-12-09 | 2015-12-09 | Chilblain therapeutic agent and production method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105434467A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105878273A (en) * | 2016-04-21 | 2016-08-24 | 武汉时代珍传医疗器械有限公司 | Ear acupoint pressing bean and preparation method thereof |
| CN108175949A (en) * | 2018-01-09 | 2018-06-19 | 山东权科生物技术有限公司 | A kind of physical therapy material and preparation method thereof |
| CN110772530A (en) * | 2019-12-18 | 2020-02-11 | 和也健康科技有限公司 | Blood circulation promoting composition and protective finger stall |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1308940A (en) * | 2000-11-28 | 2001-08-22 | 高翠霞 | Application and preparing process of nm-class biological medical stone powder |
| CN1480045A (en) * | 2003-07-21 | 2004-03-10 | 艳 林 | Broad-spectrum antibacterial nano ointment |
| CN202437982U (en) * | 2012-02-23 | 2012-09-19 | 刘帆 | External-use medicine package for hemorrhoids preventive treatment |
-
2015
- 2015-12-09 CN CN201510899238.7A patent/CN105434467A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1308940A (en) * | 2000-11-28 | 2001-08-22 | 高翠霞 | Application and preparing process of nm-class biological medical stone powder |
| CN1480045A (en) * | 2003-07-21 | 2004-03-10 | 艳 林 | Broad-spectrum antibacterial nano ointment |
| CN202437982U (en) * | 2012-02-23 | 2012-09-19 | 刘帆 | External-use medicine package for hemorrhoids preventive treatment |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105878273A (en) * | 2016-04-21 | 2016-08-24 | 武汉时代珍传医疗器械有限公司 | Ear acupoint pressing bean and preparation method thereof |
| CN108175949A (en) * | 2018-01-09 | 2018-06-19 | 山东权科生物技术有限公司 | A kind of physical therapy material and preparation method thereof |
| CN108175949B (en) * | 2018-01-09 | 2019-09-20 | 山东权科生物技术有限公司 | A kind of physical therapy material and preparation method thereof |
| CN110772530A (en) * | 2019-12-18 | 2020-02-11 | 和也健康科技有限公司 | Blood circulation promoting composition and protective finger stall |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI352597B (en) | Composition having effect of moxibustion and press | |
| CN103393916B (en) | External use ointment used for treating dermatitis and preparation method thereof | |
| CN103007153A (en) | Health-care traditional Chinese medicine scented sachet | |
| CN103007147A (en) | Traditional Chinese medicine scented sachet for preventing influenza | |
| CN103070996A (en) | Traditional Chinese medicine sachet used for preventing and treating influenza | |
| CN105434467A (en) | Chilblain therapeutic agent and production method thereof | |
| CN102988859A (en) | Traditional Chinese medicine sachet | |
| CN106075000A (en) | A kind of Chinese medicine ointment for treating hemorrhoid and preparation method thereof | |
| CN100393332C (en) | Tissue regenerating ointment with repercussive and toxin-draining functions | |
| CN104623432B (en) | A kind of Chinese medicine composition for treating tumour | |
| CN103007155A (en) | Traditional Chinese medicine scented sachet for preventing and treating common cold | |
| CN105477446A (en) | Traditional Chinese medicinal composition for treating verruca plana | |
| CN103006940A (en) | Traditional Chinese medicine scented sachet for preventing influenza | |
| CN105168091A (en) | Telangiectasis removing mask powder and preparation method thereof | |
| CN109700844A (en) | A kind of externally applied drug and preparation method thereof for treating serious case of furuncle | |
| CN104257777B (en) | Traditional Chinese medicine composition for treating rhinitis, nasosinusitis and frontal sinusitis and preparation method of traditional Chinese medicine composition | |
| CN103006733A (en) | Traditional Chinese medicine scented sachet for preventing influenza | |
| CN102512650A (en) | Externally-used medicine for treating facial paralysis | |
| CN106728069A (en) | It is a kind of to treat the putrefaction-removing granulation-promoting paste for scalding burn | |
| CN104958653A (en) | Traditional Chinese medicine composition for treating tuberculosis | |
| CN104027391A (en) | Traditional Chinese medicine lotion for treating sweat stains | |
| Axe et al. | The Essential Oils Home Remedy Guide | |
| CN108452297A (en) | The quickly Chinese medicine and preparation method thereof for the treatment of wart | |
| CN103006778A (en) | Traditional Chinese medicine scented sachet for preventing and treating common cold | |
| CN103007128A (en) | Health-care traditional Chinese medicine scented sachet |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160330 |